Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1989 4
1990 7
1991 6
1992 6
1993 5
1994 12
1995 16
1996 6
1997 3
1998 3
1999 2
2000 4
2002 4
2003 2
2004 3
2005 1
2006 2
2007 4
2010 1
2011 1
2012 4
2018 1
2019 1
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Clinical experience with cefpodoxime proxetil in acute otitis media.
Cohen R. Cohen R. Pediatr Infect Dis J. 1995 Apr;14(4 Suppl):S12-8. doi: 10.1097/00006454-199504001-00003. Pediatr Infect Dis J. 1995. PMID: 7792125 Review.
This has led to a search for therapeutic alternatives to the reference treatment, which is still amoxicillin in many countries. Cefpodoxime proxetil is one such alternative. Six comparative randomized trials of cefpodoxime proxetil in childhood acute otitis media ha …
This has led to a search for therapeutic alternatives to the reference treatment, which is still amoxicillin in many countries. Cefpodoxi …
Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections.
Safran C. Safran C. J Antimicrob Chemother. 1990 Dec;26 Suppl E:93-101. doi: 10.1093/jac/26.suppl_e.93. J Antimicrob Chemother. 1990. PMID: 2292535 Review.
The clinical response was judged satisfactory in 1205/1263 (95.4%) patients treated with cefpodoxime proxetil and in 788/838 (94%) patients treated with comparative antibiotics. The bacteriological response was judged satisfactory for 662/699 (95%) pathogens for cefpodo …
The clinical response was judged satisfactory in 1205/1263 (95.4%) patients treated with cefpodoxime proxetil and in 788/838 (94%) pa …
Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
Geddes AM. Geddes AM. Drugs. 1991;42 Suppl 3:34-40. doi: 10.2165/00003495-199100423-00008. Drugs. 1991. PMID: 1726206 Review.
Cefpodoxime proxetil is the orally absorbed ester of cefpodoxime, a new third generation cephalosporin. ...Thus, cefpodoxime proxetil is a useful addition to the antibacterials available for the treatment of infections of the lower respiratory tract....
Cefpodoxime proxetil is the orally absorbed ester of cefpodoxime, a new third generation cephalosporin. ...Thus, cefpodoxim …
Interstitial tissue concentrations of cefpodoxime.
Liu P, Müller M, Grant M, Webb AI, Obermann B, Derendorf H. Liu P, et al. J Antimicrob Chemother. 2002 Jul;50 Suppl:19-22. doi: 10.1093/jac/dkf804. J Antimicrob Chemother. 2002. PMID: 12077156 Clinical Trial.
We used microdialysis in animal and human studies to investigate the tissue penetration of cefpodoxime. In the animal study, total plasma and free muscle and lung concentrations of cefpodoxime were measured after male Wistar rats had received either 10 mg/kg or 20 m …
We used microdialysis in animal and human studies to investigate the tissue penetration of cefpodoxime. In the animal study, total pl …
[Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice].
Brambilla C, Benhamou D, Guérin JC, Kelkel E, Muir JF, Prud'homme A, Taytard A, Fauche A. Brambilla C, et al. Pathol Biol (Paris). 1995 Nov;43(9):815-24. Pathol Biol (Paris). 1995. PMID: 8746104 Clinical Trial. French.
After verification of the eligibility criteria, written consent and randomization, the patients received, for 10 days, either cefatrizine at the dose of 1 g/day or cefpodoxime proxetil at the dose of 400 mg/day. A self-assessment form was given to the patient. ...This stud …
After verification of the eligibility criteria, written consent and randomization, the patients received, for 10 days, either cefatrizine at …
Clinical and economic considerations in the use of third-generation oral cephalosporins.
Chambers ST, Murdoch DR, Pearce MJ. Chambers ST, et al. Pharmacoeconomics. 1995 May;7(5):416-27. doi: 10.2165/00019053-199507050-00006. Pharmacoeconomics. 1995. PMID: 10155329 Review.
A number of oral third-generation cephalosporins (cefixime, cefetamet pivoxil, ceftibuten and cefpodoxime proxetil) have been widely trialled and are becoming available. In addition, cefdinir may also be marketed. ...
A number of oral third-generation cephalosporins (cefixime, cefetamet pivoxil, ceftibuten and cefpodoxime proxetil) have been widely …
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.
Saathoff N, Lode H, Neider K, Depperman KM, Borner K, Koeppe P. Saathoff N, et al. Antimicrob Agents Chemother. 1992 Apr;36(4):796-800. doi: 10.1128/AAC.36.4.796. Antimicrob Agents Chemother. 1992. PMID: 1354432 Free PMC article. Clinical Trial.
Cefpodoxime proxetil is a new oral esterified cephem antibiotic with a broad antibacterial spectrum. ...For the statistical evaluation, these data were tested by using the pharmacokinetics of 0.2 g of cefpodoxime proxetil from the first study. The maximum concentrat …
Cefpodoxime proxetil is a new oral esterified cephem antibiotic with a broad antibacterial spectrum. ...For the statistical evaluatio …
[Pharmacokinetic and clinical studies on cefpodoxime proxetil dry syrup in the field of pediatrics].
Motohiro T, Oda K, Aramaki M, Kawakami A, Tanaka K, Koga T, Sakata Y, Fujimoto T, Yokochi K, Yamashita F, et al. Motohiro T, et al. Jpn J Antibiot. 1989 Jul;42(7):1629-66. Jpn J Antibiot. 1989. PMID: 2681864 Clinical Trial. Japanese.
Cefpodoxime proxetil (CPDX-PR, CS-807) is a new oral cephem derivative drug in which carboxylic acid was esterified to the 4-position of CPDX (oxime type cephem antibiotic). ...
Cefpodoxime proxetil (CPDX-PR, CS-807) is a new oral cephem derivative drug in which carboxylic acid was esterified to the 4-position …
Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.
Borin MT, Hughes GS, Spillers CR, Patel RK. Borin MT, et al. Antimicrob Agents Chemother. 1990 Jun;34(6):1094-9. doi: 10.1128/AAC.34.6.1094. Antimicrob Agents Chemother. 1990. PMID: 2393268 Free PMC article. Clinical Trial.
The single-dose and steady-state pharmacokinetics of cefpodoxime were assessed in plasma and skin blister fluid (SBF) after oral dosing of 200 mg (n = 8) and 400 mg (n = 8) of cefpodoxime proxetil (doses are expressed as cefpodoxime equivalents) in healthy su …
The single-dose and steady-state pharmacokinetics of cefpodoxime were assessed in plasma and skin blister fluid (SBF) after oral dosi …
Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.
Borin MT, Hughes GS, Patel RK, Royer ME, Cathcart KS. Borin MT, et al. J Clin Pharmacol. 1991 Dec;31(12):1137-45. doi: 10.1002/j.1552-4604.1991.tb03686.x. J Clin Pharmacol. 1991. PMID: 1761737 Clinical Trial.
Cefpodoxime proxetil, a third generation, broad-spectrum, oral cephalosporin, was administered in single doses of 100, 200, 400, 600, and 800 mg (dose expressed as cefpodoxime equivalents) and multiple doses of 100, 200, and 400 mg twice daily to healthy volunteers. …
Cefpodoxime proxetil, a third generation, broad-spectrum, oral cephalosporin, was administered in single doses of 100, 200, 400, 600, …
101 results